Sweden in Global ATMP Research

A data-driven benchmarking platform supporting Sweden's application to the VR/VINNOVA Excellence Clusters for Groundbreaking Technologies programme.

Advanced Therapy Medicinal Products (ATMPs) include gene therapies, cell therapies, and tissue-engineered products, regulated in the EU under Regulation 1394/2007. They represent one of the most transformative and commercially significant frontiers in modern medicine. This platform maps Sweden's position across more than 900,000 ATMP publications from 192 countries, covering 1990 to 2024.

Every module can be filtered by year range and ATMP technology domain. Use the controls at the top of each page to interrogate the evidence on your own terms.

Data sources: Dimensions Research Publications Database (Digital Science), publications, citations, and clinical trial links. Altmetric Details API (Digital Science), patent, policy, guideline, news, and blog mention events. NIH iCite, Relative Citation Ratio (RCR). SCImago Journal Rankings, journal-level prestige scores (SJR). Commercial and scientific potential scores: Masclans, R., Hasan, S., and Cohen, W. M. (2025), Strategic Management Journal, 46(9), dataset at https://zenodo.org/records/17912043 (commercial potential v3; scientific potential v2). ATMP subject classification: 112 Medical Subject Headings (MeSH) 2026 descriptors, identified by keyword and tree-number matching, independently validated by a domain expert in ATMP biology. Coverage: 1990–2024. Data extracted May 2026. Publications from late 2024 may be undercounted due to indexing lag. Analysis: Yotam Sofer, House of Innovation, Stockholm School of Economics.